HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA denies sunscreen petition

This article was originally published in The Rose Sheet

Executive Summary

FDA can not stay effective date of any pending decision to exempt "sunscreen face products" from OTC sunscreen monograph or effective date of any labeling requirement, agency informs Playtex Jan. 31. Citizen petition requesting stays of action is denied because "there is no 'decision' or 'effective date'...which can be stayed," FDA says. Banana Boat manufacturer/marketer submitted petition urging uniform labeling for sunscreen products in late 2000 in opposition to cosmetics industry requests that products for face, hands and neck be granted labeling exemptions (1"The Rose Sheet" Jan. 22, 2001, p. 9)...

You may also be interested in...

Sunscreen Uniform Labeling Endorsed By Playtex, Contested By CTFA

Uniform labeling on all sunscreen products is necessary to eliminate consumer confusion, subsequent misuse and perceived failure of such items, Playtex maintains in comments to FDA Jan. 5.

DevaCurl Faces Multiple Class Actions As Latest Brand Linked To Hair Loss

The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.

Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?

To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts